Skip to main content

Table 1 Baseline Characteristics

From: Characterization of vitamin D supplementation and clinical outcomes in a large cohort of early Parkinson’s disease

 

No Supplement (N = 511)

MVI

D

D + MVI

P value

(N = 322)

(N = 42)

(N = 68)

 

Mean (SD)

F test

Age in years

60.1 (9.7)

61.8 (8.6)*

65.3 (6.4)*

65.5 (7.7)*

< 0.0001

Age at PD Dx

58.5 (9.7)

60.2 (8.7)*

63.9 (6.6)*

64.1 (7.7)*

< 0.0001

Yrs since Dx

1.6 (1.1)

1.7 (1.2)

1.3 (1.0)

1.4 (0.8)

0.07

Years since Dx to D-treatment

1.1 (1.1)

1.3 (1.2)

0.9 (1.0)

1.0 (0.8)

0.08

UPDRS total

25.1 (10.3)

25.4 (10.3)

25.1 (11.4)

24.5 (9.8)

0.92

UPDRS mental

1.2 (1.3)

1.2 (1.3)

1.4 (1.4)

1.2 (1.3)

0.85

UPDRS ADL

6.8 (3.7)

6.8 (3.6)

6.2 (3.9)

6.4 (3.4)

0.66

PDQ 39 summary

12.9 (10.4)

11.5 (8.7)

12.5 (9.6)

10.5 (8.3)

0.08

SCOPA COG

30.4 (5.1)

30.4 (5.2)

30.9 (4.6)

31.1 (5.0)

0.71

SDMT

45.1 (11.1)

44.4 (10.9)

45.2 (11.4)

45.9 (11.4)

0.71

Total daily LED

374.9 (224.9)

371.3 (232.8)

390.0 (208.0)

367.4 (355.4)

0.96

 

Frequency (%)

X2testa

Female %

144 (28.2%)

94 (29.2%)

27 (64.3%)

38 (55.9%)

< 0.0001

Non-Hispanic white

448 (87.7%)

303 (94.1%)

41 (97.6%)

66 (97.1%)

0.001

Education > 17 yearsa

149 (29.2%)

118 (36.7%)

16 (38.1%)

18 (26.5%)

0.08

  1. Abbreviations: PD Parkinson’s disease, Dx diagnosis, yrs years, D-treatment dopaminergic treatment (dopamine agonist or levodopa), UPDRS Unified Parkinson’s Disease Rating Scale, ADL activities of daily living, PDQ Parkinson’s disease questionnaire, SCOPA COG Scales for outcomes of Parkinson’s disease-Cognition, SDMT symbol digit modalities test, LED levodopa equivalent dose
  2. *p < .05 compared to NoSupp, according to pairwise comparisons Hochberg method
  3. aX2 test was calculated by Fisher’s exact test